Infantile spasms (IS) is an age-specific epilepsy which responds to anticonvulsant therapy but has a generally poor prognosis for normal psychomotor development. The subgroup of infants with a cryptogenic aetiology or whose therapy is initiated promptly is thought to have a more favourable prognosis. We retrospectively reviewed 28 infants with IS treated between 1990 and 1996 with adrenocorticotropic hormone (ACTH), valproic acid (VPA), or both, in order to correlate therapeutic response with long-term outcome. Mean age at onset of treatment was 6.4 months, with 57% of patients started within 1 month of IS appearance. IS was considered cryptogenic in 39%. The majority of infants responded to ACTH or VPA with a reduction in spasms of 75% or more. Total remission of seizures occurred in 52%. Death occurred in eight patients; mean duration of follow-up for survivors was 55 months. All subgroups based on age, aetiology, or treatment had poor outcomes, commonly with residual epilepsy, cerebral palsy or mental retardation. Conventional treatment for IS, even when initially successful in reducing spasms, is inadequate when viewed from a long-term developmental perspective, suggesting the need for novel innovative approaches for treating IS.
Infantile spasms (IS) is a poorly understood, age-specific epilepsy which has a poor prognosis for subsequent normal development'**. Although reports indicate a high success rate of seizure control with adrenocorticotropic hormone (ACTH) therapy", no studies have demonstrated an equivalent recovery of neurodevelopmental milestones which are lost with the onset of IS. Advances in neuroimaging have permitted a sharper distinction between symptomatic and cryptogenic causes of IS'.', but the ability to determine which children develop normally following ACTH therapy has not been realized%lo. Nevertheless, ACTH is considered standard therapy for IS, despite a high incidence of side-effects, inability to be used for long periods of time, inefficacy for other seizure types, and unreliable availability.
Intermittently, there has been interest in other drugs for control of IS, particularly valproic acid (VPA)"-15, which has been used primarily when ACTH has failed. We report our experience with 28 infants who were newly diagnosed with IS and treated between 1990 and 1995 with either ACTH or VPA as l/97/030201 + 05 $12.00/O primary therapy and the other drug as alternative therapy and their long-term outcomes following treatment.
METHODS
A diagnosis of IS was made in infants who demonstrated clusters of clinical spasms and a hypsarrhythmic pattern on electroencephalography (EEG). IS was deemed to be cryptogenic if no etiology for seizures could be established following magnetic resonance imaging, metabolic screening, and genetic studies. In only one infant, initially evaluated at another university medical centre, was computed tomography used in place of magnetic resonance imaging. Developmental status was not used to place infants in the symptomatic or cryptogenic groups.
We conducted a retrospective review and analysis of medical records approved by the hospital review board for human research for 28 infants referred and diagnosed with IS over a B-year period from January, 1990 to December 1995, at the Children's Hospital of the Medical University of South Carolina. Treatment of these infants was standardized over the period of the study. After discussion of risks and benefits of therapy with ACTH and with VPA, parents were given the option of choosing the primary therapy. Infants receiving ACTH were started on ACTH gel (20 U) given intramuscularly per day and increased by 10 U every 3 days until seizures were controlled; a maximum dose of 80 U per day was reached and proven ineffective, or side-effects developed and prompted tapering of the drug. Parents were taught to give ACTH shots and infants were monitored at home with homehealth nurses checking urine glucose, blood pressures, and for signs of gastrointestinal bleeding. For infants receiving VPA, medication was initiated after additional screening for hematological or liver abnormalities and organic acid disorders, and other anticonvulsant medications were being tapered. The starting dose of VPA was lOmg/kg/day, increasing over 3 weeks to 60 mg/kg/day, with trough blood levels rarely exceeding 120mg/l.
VPA was increased until seizures were controlled, blood levels of llO-120 mg/l were reached and proven ineffective, or side-effects developed and prompted tapering of the drug. Regular monitoring included haemogram with reticulocyte count, liver function studies, ammonia, amylase and carnitine. Seizure frequency was monitored by the parents and (when available) the visiting nurse and recorded on seizure calendars. Greater than 75% reduction in seizure frequency was used as the indication for a positive response to therapy.
If ACTH or VPA as primary therapy proved to be ineffective or poorly tolerated by an infant after 2 or 3 weeks, the parents were encouraged to use the other drug as alternative therapy, in the hope of obtaining the best long-term neurological outcome with early control of IS.
In reviewing outcome following treatment, a patient was considered to have mental retardation if the language developmental quotient or verbal skills on IQ testing were below 70. A patient was considered to have cerebral palsy if the clinical records documented a nonprogressive motor deficit since infancy and the motor developmental quotient was below 70. Neither diagnosis was considered if there was no suspicion of abnormality at follow-up after 13 months of age, or if death occurred at or before 13 months of age. A patient was considered to have later seizures (epilepsy) if unprovoked, afebrile epileptic seizures developed and required anticonvulsant medication.
RESULTS
The 28 infants in the study included 18 boys (64%) and 10 girls (36%), with 20 whites (71%) and eight blacks (29%). Age of onset of IS ranged from 1 to 13 months, with a median of 4.0 months and a mean of 4.6 months. Neonatal seizures occurred in 46% of the subjects prior to onset of IS, and IS presented before age 6 months in 68% of patients. Age at beginning of treatment ranged from 1 to 15 months, with a mean of 6.4 months. Seventeen infants were classified as symptomatic (61%) and 11 as cryptogenic (39%). The aetiologies for the symptomatic group included perinatal insult (6), genetic (e.g. tuberous sclerosis) (4), cerebral dysgenesis (3) cerebral dysgenesis with agenesis of the corpus callosum (1) metabolic (2), and prenatal insult (1) .
Five patients had been treated with phenobarbital before referral to our centre; three of these were started on ACTH and one was started on VPA. IS resolved in one child during initial phenobarbital treatment, and neither ACTH nor VPA was started. Therefore, at the outset of this study, primary therapy was ACI'H in 11 patients and VPA in 16 patients. Later, six infants received ACTH as alternative therapy, and four infants received VPA as alternative therapy. Therefore, a total of 10 infants received both ACTH and VPA at separate times. Among infants receiving ACTH, 64% showed an initial, positive response to ACTH as primary therapy, and 83% showed a response to it as alternative therapy; there was therefore a 71% total response to ACTH. Among infants receiving VPA, 56% showed a positive response to VPA as primary therapy, and 50% showed a response as alternative therapy, therefore there was a 55% total response to VPA. There was no statistically significant difference in response between treatment groups.
Total remission of IS with treatment occurred in 14 infants (52%), six of whom received ACTH as primary therapy, three of whom received VPA as primary therapy, and five of whom received both ACTH and VPA. Long-term outcome did not differ significantly between the 11 patients treated initially with ACTH and the 16 patients treated initially with VPA [Table l(a) and (b)]. Nor did outcome differ significantly between the 17 patients with symptomatic IS and the 11 patients with cryptogenic IS (Table 2) . Comparison of long-term outcomes in the groups who received ACTH only, VPA only, or ACTH and VPA were strikingly similar for other seizure occurrence, cerebral palsy, mental retardation, minor neurological abnormalities, and death. The most convincing finding for all groups was that long-term prognosis was poor: epilepsy developed later in 21 of 25 (84%), various types of cerebral palsy in 21 of 25 (84%), and mild, moderate, or severe mental retardation in 23 of 25 (92%). Death occurred in eight patients, aged from 4 to 38 months; the mean age at death was 20 months. Follow-up for the 20 survivors ranged from 23 to 88 months after initial diagnosis of IS: the mean duration of follow-up for survivors was 55 months. Of the eight deaths, only one was related to treatment (sepsis while on ACTH); the others died from their underlying disease. Only two infants (7%) had mild non-handicapping conditions: well-controlled seizures in one, and monoparesis in the other. None of the children was neurologically normal at the conclusion of the follow-up period.
We were unable to validate earlier findings that rapid institution of treatment correlates with improved outcome (Table 3 ). This study found that treatment for IS was begun within 30 days of seizure onset in 57% of patients and after 30 days in 43% of patients. The symptomatic and cryptogenic IS patients were evenly divided between both early treatment and late treatment groups. The incidence of death and of other The findings of this retrospective study add to the abundance of published data that challenge conventional thinking about IS. Firstly, the prospects for a favourable outcome are not as good as paediatricians often lead patients to believe. This study, like others, failed to replicate the guardedly optimistic results of Bellman16, who reported that, of 267 patients with infantile spasms, 30% later had normal intelligence and only 26% went on to develop epilepsy. We found cognitive impairment in 92% of our patient population and observed that 84% developed later epilepsy. There appears to be little basis for the current teaching that one-third of infants with IS may be normal following treatment. Criteria predictive of a favourable outcome" include age of onset greater than 6 months. Our experience, which is typical of most small referral centres, showed that 68% of patients with IS presented at less than 6 months of age. Furthermore, our experience fails to confirm that better results can be achieved with prompt treatment, as proposed by others's*19.
Secondly, ACTH appears to be an effective, but not a superior drug, whether it is given in a low dose2o*2' or a high dose2*4*s. While some investigators have observed that outcome with ACTH is no different from without any treatment8*22Yu, others continue to find only 'relatively normal development' in a minority of patients24*E. Our findings suggest that VPA is as effective as ACTH in promoting remission of IS and as ineffective as ACTH in facilitating later normal cognitive development.
Thirdly, the findings demonstrate that conventional strategies for treating IS are reasonably successful in treating seizures but less adequate if long-term outcomes are used as a measure of success. When viewed from this perspective of global function rather than seizure control, it seems that none of our current drugs for treating IS produces a satisfactory outcome beyond seizure control. Whether the standard therapy with ACTH or alternative therapy with VPA is used, the likelihood of normal development remains very small. This is most probably an indication that IS and cognitive impairment are both consequences of underlying brain dysfunction, and that satisfactory treatment of the
